Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, researchers examined the concentration of cortisol in scalp hair of individuals with alopecia areata to explore its relationship with disease variables, as cortisol in hair can indicate chronic stress, which may impact alopecia areata pathogenesis.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.

This article reviews existing research on the treatment of alopecia areata using growth factors and microneedling, reporting that these methods show promise in promoting hair growth without major adverse effects, but emphasizes the need for additional large-scale studies to confirm their efficacy and safety.

This case study reports that platelet-rich plasma treatment led to total hair regrowth in a 71-year-old woman with alopecia areata who had not responded to previous standard therapies.

This review highlights that alopecia areata, a common type of hair loss, currently lacks preventive or curative treatments, and traditional therapies such as minoxidil and corticosteroids offer inconsistent results, necessitating patient-consensual treatment planning.

This study found that intralesional triamcinolone acetonide is more effective and faster than platelet-rich plasma in promoting hair regrowth for scalp alopecia areata.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

This systematic review observed that Janus kinase inhibitors show promising efficacy for treating alopecia areata, but more studies on adolescent treatments and patient-relevant outcomes are needed.

In this study, intralesional triamcinolone acetonide was found to be more effective than platelet rich plasma and placebo for moderate to severe alopecia areata, but had a higher relapse rate.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This article discusses the etiology, clinical presentation, and current treatment options for alopecia areata and highlights new therapeutic modalities under investigation, but it reports no new research results.

This review analyzed 19 studies and found that platelet-rich plasma generally led to successful hair growth in patients with alopecia, particularly suggesting 3 to 4 monthly treatment sessions.

This paper discusses the various causes and types of alopecia and presents no original research findings.

This review discusses the pathogenesis and new treatments for alopecia areata, highlighting the role of the hair follicle's immune and hormone systems and potential therapies like JAK inhibitors and immunomodulators.

This review discusses treatments for androgenic alopecia, noting that current options like finasteride and minoxidil are effective for only 10% of patients, thus highlighting the need for new therapies.

This study evaluated the accuracy of the HairCheck device, a cross-section trichometer, and concluded that it effectively measures changes in hair diameter and density for assessing alopecia progression and treatment response.

This study found that certain polymorphisms in EGF and EGFR genes may increase susceptibility to alopecia areata in the Korean population, and these genetic variations could be associated with specific symptoms such as nail involvement and body hair loss.

This review discusses the use, efficiency, and preparation methods of autologous platelet concentrates in wound healing and periodontal regeneration, but it reports no new clinical findings.

In this study, researchers administered intravenous autologous activated platelet-rich plasma (aaPRP) to 611 patients and reported no adverse events, suggesting that this treatment is safe even for patients with various pathological conditions.

This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.

This article reviews alopecia areata as a chronic autoimmune disease affecting hair follicles and discusses its association with other autoimmune conditions, but provides no new clinical findings.

The authors concluded that while PRP is a promising and well-tolerated treatment for early to moderate knee osteoarthritis, standardizing preparation protocols, patient selection, and outcome reporting is crucial to enhance comparability and inform clinical practice.

This review discusses the applications of platelet-rich plasma for non-scarring alopecia, including AGA and AA, but reports no new clinical results.

In this randomized double-blind study, 160 adults with alopecia areata showed significant improvements in hair loss severity after using a bioactive peptide cosmetic product that mimics platelet-rich plasma, while the placebo group showed no significant change, underlining the treatment's potential effectiveness.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This systematic review indicates that a platelet-rich plasma concentration of 1.0 × 10^6 plt/μL may be optimal for tissue regeneration due to sufficient nutrition supply and effective growth factor diffusion in vivo.

This review reports that platelet-rich plasma may be more effective for musculoskeletal conditions when prepared with high platelet doses and low leukocyte content, but further trials are needed to confirm optimal formulations.

This review explores the potential benefits of platelet-rich plasma for anti-aging and tissue regeneration, especially in orthopedic applications like osteoarthritis, but it reports no new clinical results.

This study concluded that repeated platelet-rich plasma injections provided greater and more consistent improvements in stress urinary incontinence symptoms compared to pelvic floor muscle training.

This review suggests that platelet-rich plasma injections may be an effective treatment for greater trochanteric pain syndrome, but emphasizes the need for more high-quality trials to confirm these findings.